Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The efficacy and tolerability of changing regimen from recombinant human erythropoietin (rhuepo) to darbepoetin alfa in chronic hemodialysis patients

  • At: 2007 FIP Congress in Beijing (China)
  • Type: Poster
  • By: TSAI, Pin-Chin (E-DA HOSPITAL/I-SHOU UNIVERSITY, Kaohsiung, China Taiwan)
  • Co-author(s): Liu, Hui-Pine (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
    Lin, Mei-Fang (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
    Chang, Min-Yu (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
    Wu, Chia-Chun (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
    Wang, Yu-Ting (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
    Hung, Shih-Yuan (E-Da Hospital, I-Shou University, KAOHSIUNG, China Taiwan)
  • Abstract:

    Darbepoetin alfa is an improvement type of erythropoietic agent with a 3-fold longer elimination half-life than recombinant human erythropoietin (rHuEpo), which has been shown to allow less frequent dosing in the treatments of renal anemia. The objective of this study was to observe the efficacy and tolerability of shifting from rHuEpo-beta (Roche ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses